{
  "docking_scores": {
    "excellent": {
      "range": "< -8.0",
      "description": "Very strong binding, potential drug candidate",
      "recommendation": "High priority for further development and experimental validation"
    },
    "good": {
      "range": "-6.0 to -8.0", 
      "description": "Good binding affinity, worth further investigation",
      "recommendation": "Worth investigating further, consider lead optimization"
    },
    "moderate": {
      "range": "-4.0 to -6.0",
      "description": "Moderate binding, may need optimization", 
      "recommendation": "May need structural modifications to improve binding"
    },
    "weak": {
      "range": "> -4.0",
      "description": "Weak binding, unlikely to be effective",
      "recommendation": "Unlikely to be effective, consider different chemical scaffolds"
    }
  },
  "targets": {
    "HSP90AA1": {
      "name": "Heat shock protein 90 alpha",
      "description": "Molecular chaperone involved in protein folding and stability",
      "drug_examples": ["Geldanamycin", "17-AAG", "Ganetespib"],
      "binding_site": "ATP binding site in N-terminal domain",
      "therapeutic_area": "Oncology, Neurodegenerative diseases",
      "dockstring_id": "HSP90AA1"
    },
    "ACHE": {
      "name": "Acetylcholinesterase",
      "description": "Enzyme that breaks down acetylcholine neurotransmitter",
      "drug_examples": ["Donepezil", "Rivastigmine", "Galantamine"],
      "binding_site": "Catalytic site with choline binding pocket",
      "therapeutic_area": "Alzheimer's disease, Myasthenia gravis",
      "dockstring_id": "ACHE"
    },
    "EGFR": {
      "name": "Epidermal Growth Factor Receptor",
      "description": "Tyrosine kinase receptor involved in cell growth",
      "drug_examples": ["Gefitinib", "Erlotinib", "Osimertinib"],
      "binding_site": "ATP binding site", 
      "therapeutic_area": "Oncology",
      "dockstring_id": "EGFR"
    },
    "F2": {
      "name": "Thrombin",
      "description": "Key enzyme in blood coagulation cascade",
      "drug_examples": ["Dabigatran", "Argatroban", "Bivalirudin"],
      "binding_site": "Active site with specificity pocket",
      "therapeutic_area": "Anticoagulation therapy",
      "dockstring_id": "F2"
    },
    "PLK1": {
      "name": "Protein kinase 1",
      "description": "Serine/threonine kinase involved in cell cycle progression",
      "drug_examples": ["Palbociclib", "Ribociclib", "Abemaciclib"],
      "binding_site": "ATP binding site",
      "therapeutic_area": "Oncology",
      "dockstring_id": "PLK1"
    },
    "ESR1": {
      "name": "Estrogen receptor 1",
      "description": "Steroid receptor involved in estrogen signaling",
      "drug_examples": ["Tamoxifen", "Fulvestrant", "Aromatase inhibitors"],
      "binding_site": "Estrogen response element",
      "therapeutic_area": "Oncology",
      "dockstring_id": "ESR1"
    }
  },
  "processes": {
    "docking": {
      "description": "Molecular docking predicts how ligands bind to protein targets by sampling different conformations and orientations",
      "steps": [
        "Prepare protein structure (remove water, add hydrogens)",
        "Define binding site", 
        "Generate ligand conformations",
        "Score binding poses",
        "Rank results by binding affinity"
      ],
      "software": ["AutoDock Vina", "Schrödinger Glide", "OpenEye FRED"]
    },
    "virtual_screening": {
      "description": "High-throughput computational screening of large compound libraries against protein targets",
      "steps": [
        "Prepare compound library",
        "Filter by drug-likeness",
        "Dock compounds to target", 
        "Score and rank results",
        "Select hits for experimental validation"
      ],
      "advantages": ["Cost-effective", "Fast", "Large scale"]
    },
    "drug_discovery": {
      "description": "Process of identifying, optimizing, and developing new therapeutic compounds",
      "stages": [
        "Target identification",
        "Hit identification", 
        "Lead optimization",
        "Preclinical development",
        "Clinical trials"
      ],
      "timeline": "10-15 years average"
    }
  },
  "molecular_properties": {
    "lipophilicity": {
      "description": "Measure of how well a compound dissolves in lipids vs water",
      "importance": "Affects membrane permeability and bioavailability", 
      "optimal_range": "LogP 1-3"
    },
    "molecular_weight": {
      "description": "Mass of the molecule",
      "importance": "Affects drug-likeness and ADMET properties",
      "optimal_range": "< 500 Da"
    },
    "polar_surface_area": {
      "description": "Surface area of polar atoms",
      "importance": "Predicts oral bioavailability",
      "optimal_range": "< 140 Å²"
    },
    "hydrogen_bond_donors": {
      "description": "Number of hydrogen bond donor groups",
      "importance": "Affects membrane permeability",
      "optimal_range": "< 5"
    },
    "hydrogen_bond_acceptors": {
      "description": "Number of hydrogen bond acceptor groups", 
      "importance": "Affects membrane permeability",
      "optimal_range": "< 10"
    }
  }
}
